VANCOUVER, British Columbia (AP) _ Novelion Therapeutics Inc. (NVLN) on Thursday reported a loss of $49.7 million in its third quarter.
The Vancouver, British Columbia-based company said it had a loss of $2.67 per share. Losses, adjusted for non-recurring costs and amortization costs, came to 89 cents per share.
The retinal disease treatment developer posted revenue of $28.7 million in the period.
Novelion Therapeutics expects full-year revenue in the range of $135 million to $145 million.